Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
The world of cell therapy has been eclipsed by the early success of oncology companies specializing in adoptive T-cell therapy or ACT. Other companies focusing on various types of multipotent stem cells have been working in the shadows, with little support from the press or the investment community.
But that might be about to change. Mesoblast Ltd.recently posted positive results in a Phase III trial of MSC-100-IV,...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
